Edmond DE Rothschild Holding S.A. Lowers Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Edmond DE Rothschild Holding S.A. decreased its position in shares of Moderna, Inc. (NASDAQ:MRNAGet Rating) by 2.3% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 140,543 shares of the company’s stock after selling 3,336 shares during the period. Edmond DE Rothschild Holding S.A.’s holdings in Moderna were worth $20,077,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in MRNA. Total Clarity Wealth Management Inc. purchased a new stake in Moderna during the second quarter valued at about $25,000. Oliver Lagore Vanvalin Investment Group bought a new position in shares of Moderna during the first quarter valued at about $30,000. FinTrust Capital Advisors LLC grew its stake in shares of Moderna by 754.5% during the second quarter. FinTrust Capital Advisors LLC now owns 188 shares of the company’s stock valued at $31,000 after buying an additional 166 shares during the last quarter. Legacy CG LLC bought a new position in shares of Moderna during the second quarter valued at about $34,000. Finally, OLD Second National Bank of Aurora bought a new position in shares of Moderna during the first quarter valued at about $39,000. Hedge funds and other institutional investors own 60.76% of the company’s stock.

Insiders Place Their Bets

In other Moderna news, insider Shannon Thyme Klinger sold 478 shares of the firm’s stock in a transaction dated Thursday, September 8th. The shares were sold at an average price of $137.44, for a total value of $65,696.32. Following the completion of the sale, the insider now directly owns 3,949 shares in the company, valued at $542,750.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Shannon Thyme Klinger sold 478 shares of Moderna stock in a transaction that occurred on Thursday, September 8th. The shares were sold at an average price of $137.44, for a total transaction of $65,696.32. Following the completion of the transaction, the insider now directly owns 3,949 shares in the company, valued at $542,750.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Stephane Bancel sold 40,000 shares of Moderna stock in a transaction that occurred on Thursday, October 20th. The shares were sold at an average price of $120.83, for a total transaction of $4,833,200.00. Following the transaction, the chief executive officer now owns 5,411,946 shares of the company’s stock, valued at $653,925,435.18. The disclosure for this sale can be found here. Insiders sold 483,436 shares of company stock worth $64,832,812 over the last three months. Company insiders own 17.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on MRNA. The Goldman Sachs Group raised their price objective on Moderna from $290.00 to $296.00 and gave the company a “buy” rating in a research note on Thursday, October 13th. Cowen reduced their price objective on Moderna from $165.00 to $145.00 in a research note on Thursday, October 20th. Chardan Capital cut their target price on Moderna from $188.00 to $186.00 and set a “buy” rating on the stock in a research note on Monday, November 7th. Deutsche Bank Aktiengesellschaft raised Moderna from a “hold” rating to a “buy” rating and raised their target price for the stock from $155.00 to $165.00 in a research note on Wednesday, September 7th. Finally, JPMorgan Chase & Co. cut their target price on Moderna from $165.00 to $122.00 and set a “neutral” rating on the stock in a research note on Monday, October 24th. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, Moderna has a consensus rating of “Hold” and an average target price of $176.93.

Moderna Stock Down 1.5 %

MRNA traded down $2.78 on Thursday, hitting $176.81. The company had a trading volume of 2,311,841 shares, compared to its average volume of 4,704,397. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.10 and a quick ratio of 1.80. Moderna, Inc. has a 52-week low of $115.03 and a 52-week high of $376.65. The stock has a fifty day simple moving average of $143.11 and a 200-day simple moving average of $146.64. The firm has a market capitalization of $67.93 billion, a P/E ratio of 6.40, a P/E/G ratio of 1.28 and a beta of 1.74.

About Moderna

(Get Rating)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

See Also

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNAGet Rating).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.